METTL21C

Across TCGA pan-cancer cohorts, METTL21C RNA differs between tumor and matched normal tissue in 8 of 18 cancer types tested, making tumor–normal expression one of METTL21C’s most consistent transcriptional readouts.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where METTL21C RNA is repressed in tumor relative to normal tissue. In most cancer types METTL21C is over-expressed in tumor, although a few such as UCEC and LUSC show the opposite, repressed pattern.

UCEC, BLCA, and LUSC are the cancer types where METTL21C tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in METTL21C RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
UCEC	All	All	−0.739	<.001	6	view →
BLCA	All	All	+0.118	.020	6	view →
LUSC	All	All	−0.200	<.001	5	view →
LUAD	Female	III,IV	−0.334	.003	4	view →
HNSC	All	All	−0.227	.016	3	view →
KIRC	Male	All	−0.027	<.001	3	view →
PRAD	All	All	−0.494	.001	2	view →
KICH	All	All	+0.301	.016	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 8 strongest of 8 lineages.

METTL21C–UCEC

Open the UCEC breakdown →